Asset Acquisition, Additional Payment Term

No definition available.

Name:	akba_AssetAcquisitionAdditionalPaymentTerm
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Additional Upfront Payment

+ References

No definition available.

+ Details

Name:	akba_AssetAcquisitionAdditionalUpfrontPayment
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

"Asset Acquisition, Consideration Transferred, Contingent Consideration, Commercial Milestone Payment

+ References

No definition available.

+ Details

Name:	akba_AssetAcquisitionConsiderationTransferredContingentConsiderationCommercialMilestonePayment
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Consideration Transferred, Contingent Consideration, Development and Regulatory Milestone Payments

+ References

No definition available.

+ Details

Name:	akba_AssetAcquisitionConsiderationTransferredContingentConsiderationDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Development Milestone Payment

+ References

No definition available.

+ Details

Name:	akba_AssetAcquisitionDevelopmentMilestonePayment
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Upfront Payment

+ References

No definition available.

+ Details

Name:	akba_AssetAcquisitionUpfrontPayment
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Commitments and contingencies.

+ References

No definition available.

+ Details

Name:	akba_CommitmentsAndContingenciesLineItems
Namespace Prefix:	akba_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cost of purchased minimum quantity product.

+ References

No definition available.

+ Details

Name:	akba_CostOfPurchasedMinimumQuantityProduct
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Expiration Period Beginning with First Commercial Sale

+ References

No definition available.

+ Details

Name:	akba_ExpirationPeriodBeginningWithFirstCommercialSale
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Long-Term Purchase Commitment, Option To Extend, Prior Notice Period

+ References

No definition available.

+ Details

Name:	akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period

+ References

No definition available.

+ Details

Name:	akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Purchase Commitment, Option For Non-Auto Renewal, Prior Written Notice Period

+ References

No definition available.

+ Details

Name:	akba_PurchaseCommitmentOptionForNonAutoRenewalPriorWrittenNoticePeriod
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage

+ References

No definition available.

+ Details

Name:	akba_RevenueRemainingPerformanceObligationVariableConsiderationRoyaltyPercentage
Namespace Prefix:	akba_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty payments due.

+ References

No definition available.

+ Details

Name:	akba_RoyaltyPaymentsDue
Namespace Prefix:	akba_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Termination Period, Prior Written Notice

+ References

No definition available.

+ Details

Name:	akba_TerminationPeriodPriorWrittenNotice
Namespace Prefix:	akba_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction cost incurred as part of consideration transferred in asset acquisition.

+ References

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The minimum amount the entity agreed to spend under the long-term purchase commitment.

+ References

No definition available.

+ Details

Name:	us-gaap_LongTermPurchaseCommitmentAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-21

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=akba_SupplyAgreementPatheonIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_SiegfriedEvionnazSAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_STAPharmaceuticalHongKongLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_WuXiSTAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_PanionBFBiotechIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_CyclerionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=akba_AcquiredLicensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akba_CyclerionAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=akba_Q32Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=akba_Q32AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands			1 Months Ended					3 Months Ended			12 Months Ended
	Nov. 28, 2025	Feb. 10, 2021	Dec. 31, 2025	Sep. 30, 2025	Dec. 31, 2024	Jun. 30, 2021	Mar. 31, 2020	Mar. 31, 2026	Mar. 31, 2025	Jun. 30, 2021	Dec. 31, 2025	Dec. 31, 2024
Commitments And Contingencies [Line Items]
Research and development								$ 14,807	$ 9,754
Contract cost incurred in research and development activities								81,500
Supply Agreement, Patheon Inc.
Commitments And Contingencies [Line Items]
Purchase commitment, option for non-auto renewal, prior written notice period (in months)							18 months
Minimum purchase commitment								1,100
Siegfried Evionnaz SA
Commitments And Contingencies [Line Items]
Cost of purchased minimum quantity product								0
Excess firm purchase commitment charge								0			$ 800
STA Pharmaceutical Hong Kong Limited
Commitments And Contingencies [Line Items]
Excess firm purchase commitment charge								69,200
WuXi STA
Commitments And Contingencies [Line Items]
Excess firm purchase commitment charge								2,100
Purchase commitment, option to extend, prior notice period (in months)		18 months
Long-term purchase commitment, option to terminate, prior notice period (at least)		180 days
Panion & BF Biotech, Inc \| License Agreement
Commitments And Contingencies [Line Items]
Royalty payments								$ 2,300	$ 2,600
Cyclerion \| License Agreement
Commitments And Contingencies [Line Items]
Expiration period beginning with first commercial sale (in years)								10 years
Termination period, prior written notice (in days)								180 days
Cyclerion \| License Agreement \| Acquired Licenses
Commitments And Contingencies [Line Items]
Upfront payments										$ 3,000
Cyclerion \| License Agreement \| Acquired Licenses \| Research and Development Expense
Commitments And Contingencies [Line Items]
Upfront payments						$ 3,000
Cyclerion \| Cyclerion Amendment \| Acquired Licenses
Commitments And Contingencies [Line Items]
Upfront payments				$ 500	$ 1,250			$ 1,000
Contingent consideration				$ 500
Specified development and regulatory milestone payments, contingent on a product-by-product basis											197,500
Research and development			$ 1,000
Cyclerion \| Cyclerion Amendment \| Acquired Licenses \| Maximum
Commitments And Contingencies [Line Items]
Tiered royalties (as percent)								20.00%
Cyclerion \| Cyclerion Amendment \| Acquired Licenses \| Research and Development Expense
Commitments And Contingencies [Line Items]
Upfront payments												$ 1,250
Contingent consideration												$ 500
Q32 \| Q32 Asset Purchase Agreement
Commitments And Contingencies [Line Items]
Upfront payments	$ 12,800
Specified development and regulatory milestone payments, contingent on a product-by-product basis	94,500
Upfront payment	7,000
Additional upfront payment	$ 3,000							$ 3,000
Additional payment term	6 months
Development milestone payment	$ 2,000							$ 2,000
Commercial milestone payment	487,500
Asset acquisition, consideration transferred, transaction cost	$ 800
Charge for purchase of IPR&D asset											$ 12,800